Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 215

1.

Pharmacodynamic effects during the transition between cangrelor and ticagrelor.

Schneider DJ, Agarwal Z, Seecheran N, Keating FK, Gogo P.

JACC Cardiovasc Interv. 2014 Apr;7(4):435-42. doi: 10.1016/j.jcin.2013.08.017. Epub 2014 Mar 19.

2.

Pharmacodynamic effects during the transition between cangrelor and prasugrel.

Schneider DJ, Seecheran N, Raza SS, Keating FK, Gogo P.

Coron Artery Dis. 2015 Jan;26(1):42-8. doi: 10.1097/MCA.0000000000000158.

PMID:
25089928
3.

Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients.

Rollini F, Franchi F, Tello-Montoliu A, Patel R, Darlington A, Ferreiro JL, Cho JR, Muñiz-Lozano A, Desai B, Zenni MM, Guzman LA, Bass TA, Angiolillo DJ.

JACC Cardiovasc Interv. 2014 Apr;7(4):426-34. doi: 10.1016/j.jcin.2013.11.019. Epub 2014 Mar 13.

4.

Pharmacodynamic Effects of Ticagrelor Dosing Regimens in Patients on Maintenance Ticagrelor Therapy: Results From a Prospective, Randomized, Double-Blind Investigation.

Cho JR, Rollini F, Franchi F, DeGroat C, Bhatti M, Dunn EC, Ferrante E, Muniz-Lozano A, Suryadevara S, Zenni MM, Guzman LA, Bass TA, Angiolillo DJ.

JACC Cardiovasc Interv. 2015 Jul;8(8):1075-83. doi: 10.1016/j.jcin.2015.02.022. Epub 2015 Jun 24.

PMID:
26117466
5.

Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study.

Ueno M, Ferreiro JL, Desai B, Tomasello SD, Tello-Montoliu A, Capodanno D, Capranzano P, Kodali M, Dharmashankar K, Charlton RK, Bass TA, Angiolillo DJ.

JACC Cardiovasc Interv. 2012 Mar;5(3):293-300. doi: 10.1016/j.jcin.2011.09.027.

6.

Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model.

Ravnefjord A, Weilitz J, Emanuelsson BM, van Giezen JJ.

Thromb Res. 2012 Oct;130(4):622-8. doi: 10.1016/j.thromres.2012.07.021. Epub 2012 Aug 19.

PMID:
22909827
7.

Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials.

Angiolillo DJ, Schneider DJ, Bhatt DL, French WJ, Price MJ, Saucedo JF, Shaburishvili T, Huber K, Prats J, Liu T, Harrington RA, Becker RC.

J Thromb Thrombolysis. 2012 Jul;34(1):44-55. doi: 10.1007/s11239-012-0737-3.

PMID:
22569899
8.

The influence of body size on the pharmacodynamic and pharmacokinetic response to clopidogrel and prasugrel: a retrospective analysis of the FEATHER study.

Jakubowski JA, Angiolillo DJ, Zhou C, Small DS, Moser BA, Ten Berg JM, Brown PB, James S, Winters KJ, Erlinge D.

Thromb Res. 2014 Sep;134(3):552-7. doi: 10.1016/j.thromres.2014.05.019. Epub 2014 May 21.

PMID:
25022828
9.

P2Y₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP.

Iyú D, Glenn JR, White AE, Fox SC, Dovlatova N, Heptinstall S.

Platelets. 2011;22(7):504-15. doi: 10.3109/09537104.2011.576284. Epub 2011 May 19.

PMID:
21591981
10.

Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel.

Ueno M, Ferreiro JL, Tomasello SD, Tello-Montoliu A, Capodanno D, Seecheran N, Kodali M, Dharmashankar K, Desai B, Charlton RK, Bass TA, Angiolillo DJ.

JACC Cardiovasc Interv. 2011 Aug;4(8):905-12. doi: 10.1016/j.jcin.2011.05.016.

11.

Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: Results of the SWAP-2 Study (Switching Anti Platelet-2).

Angiolillo DJ, Curzen N, Gurbel P, Vaitkus P, Lipkin F, Li W, Jakubowski JA, Zettler M, Effron MB, Trenk D.

J Am Coll Cardiol. 2014 Apr 22;63(15):1500-9. doi: 10.1016/j.jacc.2013.11.032. Epub 2013 Dec 12.

12.

Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses.

Storey RF, Bliden KP, Ecob R, Karunakaran A, Butler K, Wei C, Tantry U, Gurbel PA.

J Thromb Haemost. 2011 Sep;9(9):1730-7. doi: 10.1111/j.1538-7836.2011.04419.x.

13.

Pharmacodynamic Effects When Clopidogrel is Given Before Cangrelor Discontinuation.

Schneider DJ, Agarwal Z, Seecheran N, Gogo P.

J Interv Cardiol. 2015 Oct;28(5):415-9. doi: 10.1111/joic.12229. Epub 2015 Sep 18.

PMID:
26381736
14.

Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.

Alexopoulos D, Xanthopoulou I, Gkizas V, Kassimis G, Theodoropoulos KC, Makris G, Koutsogiannis N, Damelou A, Tsigkas G, Davlouros P, Hahalis G.

Circ Cardiovasc Interv. 2012 Dec;5(6):797-804. doi: 10.1161/CIRCINTERVENTIONS.112.972323. Epub 2012 Nov 20.

15.

Cangrelor: a novel intravenous antiplatelet agent with a questionable future.

Waite LH, Phan YL, Spinler SA.

Pharmacotherapy. 2014 Oct;34(10):1061-76. doi: 10.1002/phar.1471. Epub 2014 Aug 13. Review.

PMID:
25123696
16.

Adenosine derived from ADP can contribute to inhibition of platelet aggregation in the presence of a P2Y12 antagonist.

Iyú D, Glenn JR, White AE, Fox SC, Heptinstall S.

Arterioscler Thromb Vasc Biol. 2011 Feb;31(2):416-22. doi: 10.1161/ATVBAHA.110.219501. Epub 2010 Nov 24.

17.

High on-treatment platelet reactivity assessed by various platelet function tests: is the consensus-defined cut-off of VASP-P platelet reactivity index too low?

Jeong YH, Bliden KP, Tantry US, Gurbel PA.

J Thromb Haemost. 2012 Mar;10(3):487-9. doi: 10.1111/j.1538-7836.2011.04604.x. No abstract available.

18.
19.

Switching acute coronary syndrome patients from prasugrel to clopidogrel.

Kerneis M, Silvain J, Abtan J, Cayla G, O'Connor SA, Barthélémy O, Vignalou JB, Beygui F, Brugier D, Martin R, Collet JP, Montalescot G.

JACC Cardiovasc Interv. 2013 Feb;6(2):158-65. doi: 10.1016/j.jcin.2012.09.012.

20.

Comparison of the VASP assay and platelet aggregometry in the evaluation of platelet P2Y12 receptor blockade.

Kuliczkowski W, Rychlik B, Chiżyński K, Watała C, Golański J.

Pol Arch Med Wewn. 2011 Apr;121(4):115-21.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk